FTY720 is an immune modulator and a synthetic analogue of sphingosine 1-phosphate (S1P), activated S1P receptors and is effective in experimental models of transplantation and autoimmunity.

FTY720 is a novel, once-daily, oral treatment in worldwide Phase III clinical development for the treatment of relapsing-remitting MS, the form of the disease that affects approximately 85% of ...

A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved vascularization ...

FTY720-related adverse events included dose-related, transient, generally asymptomatic heart rate reduction, infrequent transient AV conduction block, mild (1-3 mm Hg) blood pressure increase ...

Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment history Data presented at the American Academy of Neurology show ...

FTY720 was found to directly bind to I2PP2A through a ceramide-binding domain resulting in inhibition of growth in the tested human lung cancer cell lines and A549-xenograft-derived tumors. The ...

FTY720 is an oral S1P-receptor modulator that displays unique immunomodulatory properties: this agent produces a dose-dependent, reversible decrease in blood lymphocyte count resulting both from ...

Overall, FTY720 was well tolerated: treatment was discontinued because of AEs in four, five and eight patients receiving placebo, or FTY720 1.25 and 5 mg, respectively, during the 6-month core study.

FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) was a double-blind, placebo-controlled study involving 1,272 patients in 22 countries to assess the ...

Novartis AG's <NOVN.VX> once-daily FTY720 pill reduced the number of attacks suffered by patients with multiple sclerosis (MS) after three years, according to data presented on Tuesday.

Novartis SA said one patient died and another developed a serious infection in tests of its FTY720 multiple sclerosis treatment. ``Novartis was recently notified of two infection-related incidents ...